Modern CINV prevention: fewer medications, greater comfort for the patient and the therapeutic team
OncoReview · 30.09.2025 · 15 (2(58)) · 41-45
DOI: 10.24292/01.or.152991025 ↗Kurz gefasst
Fachartikel in der Zeitschrift OncoReview, online erschienen am 30.09.2025. Verfasst von Łukasz Hajac und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Nausea and vomiting are among the most frequently reported adverse effects of systemic oncological treatment. Effective prevention is key to improving patients’ quality of life. Nausea and vomiting can be early, late, or preemptive. Both the mechanism of their onset and the therapeutic methods vary. Treatment primarily involves 5-HT3 antagonists, glucocorticosteroids, NK1 antagonists, and olanzapine. Modern antiemetic therapy is safe and effective in most cases. The most common side effects include headache, constipation, and sedation.
Zitieren
APA
Hajac, Ł., Hajac, M., & Hudziec, P. (2025). Modern CINV prevention: fewer medications, greater comfort for the patient and the therapeutic team. OncoReview, 15(2(58)), 41-45. https://doi.org/10.24292/01.or.152991025
Vancouver
Hajac Ł, Hajac M, Hudziec P. Modern CINV prevention: fewer medications, greater comfort for the patient and the therapeutic team. OncoReview. 2025;15(2(58)):41-45. doi:10.24292/01.or.152991025
BibTeX
@article{Hajac2025,
author = {Hajac, Łukasz and Hajac, Martyna and Hudziec, Piotr},
title = {Modern CINV prevention: fewer medications, greater comfort for the patient and the therapeutic team},
journal = {OncoReview},
year = {2025},
volume = {15},
number = {2(58)},
pages = {41--45},
doi = {10.24292/01.or.152991025}
}
EUVIMED